Your browser is no longer supported. Please, upgrade your browser.
Settings
ROSG Rosetta Genomics Ltd. daily Stock Chart
ROSG [NASD]
Rosetta Genomics Ltd.
Index- P/E- EPS (ttm)-9.31 Insider Own16.10% Shs Outstand3.05M Perf Week-3.55%
Market Cap4.15M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.05M Perf Month-17.58%
Income-16.20M PEG- EPS next Q- Inst Own9.80% Short Float3.35% Perf Quarter-32.00%
Sales9.20M P/S0.45 EPS this Y32.50% Inst Trans41.73% Short Ratio0.91 Perf Half Y-57.76%
Book/sh2.49 P/B0.55 EPS next Y- ROA-108.90% Target Price24.00 Perf Year-87.54%
Cash/sh- P/C- EPS next 5Y15.00% ROE-155.30% 52W Range1.25 - 11.46 Perf YTD-73.02%
Dividend- P/FCF- EPS past 5Y4.40% ROI-339.80% 52W High-88.13% Beta0.64
Dividend %- Quick Ratio2.50 Sales past 5Y145.80% Gross Margin19.40% 52W Low8.80% ATR0.13
Employees86 Current Ratio2.50 Sales Q/Q-44.40% Oper. Margin- RSI (14)36.70 Volatility15.64% 8.71%
OptionableNo Debt/Eq0.05 EPS Q/Q37.80% Profit Margin- Rel Volume1.90 Prev Close1.43
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume111.96K Price1.36
Recom2.00 SMA20-11.01% SMA50-23.18% SMA200-60.64% Volume212,324 Change-4.90%
Mar-28-16Reiterated Barrington Research Outperform $5 → $3.50
Dec-18-15Initiated Cantor Fitzgerald Buy
Apr-30-15Resumed Barrington Research Outperform
Apr-17-15Upgrade Cantor Fitzgerald Hold → Buy
Oct-30-13Downgrade Aegis Capital Buy → Hold $10 → $3.50
Sep-08-17 08:30AM  Rosetta Genomics Enters into Agreement to Sell Its PersonalizeDx Business to Pragmin Prognosis ACCESSWIRE
Sep-06-17 08:30AM  Rosetta Genomics Expands Global Patent Protection for RosettaGX Reveal with Patent Allowance in Japan ACCESSWIRE -5.77%
Sep-05-17 08:30AM  Rosetta Genomics to Reduce Operating and Other Expenses ACCESSWIRE -5.45%
Aug-21-17 08:00AM  Major Clinical Reference Laboratory Selects RosettaGX Reveal Thyroid miRNA Classifier as Molecular Test of Choice ACCESSWIRE
Aug-04-17 07:00AM  Rosetta Genomics Announces Pricing of $2.73 Million Financing ACCESSWIRE
Jul-31-17 07:00AM  Clinical Utility Survey Demonstrates the Potential of RosettaGX Reveal(TM) to Significantly Reduce Unnecessary Thyroid Surgeries ACCESSWIRE -5.74%
Jul-26-17 08:30AM  RosettaGX Reveal(TM) to be Highlighted in Oral Presentation at the 3rd World Congress on Thyroid Cancer Accesswire -23.32%
Jul-06-17 08:00AM  Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China Accesswire
Jun-01-17 09:06AM  Rosetta Genomics Ltd. :ROSG-US: Earnings Analysis: Q4, 2016 By the Numbers : June 1, 2017 Capital Cube
May-25-17 08:30AM  Rosetta Genomics Granted European Patent Allowance Covering RosettaGX Cancer Origin Assay Accesswire +7.41%
May-23-17 08:00AM  Rosetta Genomics Enters Collaboration to Develop a microRNA Classifier Relating to Patients with Non-Small Cell Lung Cancer Considered for Treatment with Immuno-oncology Drugs Accesswire
May-22-17 08:00AM  Rosetta Genomics Focusing Efforts on Improving Cash Position through Sale of the PersonalizeDx Business and Monetizing IP Accesswire +6.92%
May-12-17 09:23AM  Rosetta Genomics Announces Favorable Results from Two Pilot Studies Comparing RosettaGX Reveal(TM) and the Afirma GEC Assay for the Classification of Indeterminate Thyroid Nodules Accesswire
May-05-17 08:00AM  Rosetta Genomics Expands International Access for RosettaGX Reveal(TM) through Agreement with Cytolog Laboratories in Brazil Accesswire
May-04-17 09:00AM  Rosetta Genomics Receives Final Approval from New York State for First-of-its-kind Thyroid Cancer Diagnostic Assay Accesswire -6.00%
May-02-17 09:00AM  Rosetta Genomics to Increase Investment in RosettaGX Reveal(TM) and Explore Strategic Alternatives for the PersonalizeDx Business Accesswire
May-01-17 08:30AM  Rosetta Genomics Expands Patent Portfolio in Europe and Japan Accesswire
Apr-27-17 08:45AM  New Data Highlighting the Powerful Performance of RosettaGX Reveal(TM) in Identifying Medullary Thyroid Cancer to be Presented at the AACE 2017 Annual Meeting Accesswire
Mar-30-17 06:06PM  Edited Transcript of ROSG earnings conference call or presentation 30-Mar-17 2:00pm GMT Thomson Reuters StreetEvents -16.72%
07:07AM  Full Year 2016 Rosetta Genomics Ltd Earnings Release - Before Market Open
07:00AM  Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results Accesswire
Mar-23-17 08:00AM  Rosetta Genomics to Host 2016 Fourth Quarter and Year End Financial Results and Business Update Conference Call on March 30, 2017 Accesswire
Mar-20-17 08:00AM  Rosetta Genomics Fortifies Patent Protection for its Unique RosettaGX RevealTM Assay Business Wire -6.00%
Mar-17-17 07:03AM  Splits Calendar: Rosetta Genomics splits before market open today (1:12 ratio) -16.69%
Mar-16-17 12:02PM  Rosetta Genomics Announces 1-for-12 Reverse Stock Split Business Wire -11.09%
Feb-23-17 09:43AM  Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures Business Wire
Feb-08-17 09:00AM  Rosetta Genomics Reports Preliminary RosettaGX Reveal Financial Results for the 2016 Fourth Quarter and Year Business Wire
Feb-06-17 08:00AM  Rosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx RevealTM microRNAs Business Wire
Jan-11-17 05:32PM  Aegis Restates 'Buy' Rating on Shares of Rosetta Genomics Ltd. (NAS:ROSG) ABN Newswire
Dec-20-16 08:00AM  Rosetta Genomics Reports Third Quarter 2016 Financial Results Accesswire
Dec-01-16 08:00AM  Rosetta Genomics to Present at the 9th Annual LD Micro Main Event Accesswire
Nov-30-16 07:07AM  Q3 2016 Rosetta Genomics Ltd Earnings Release - After Market Close
Nov-23-16 03:35PM  Rosetta Genomics Announces Pricing of $5 Million Concurrent Registered Direct and Private Placement Offering Business Wire -19.54%
Nov-21-16 08:00AM  Rosetta Genomics Enters Research Collaboration using microRNA Biomarkers to Predict Response to Leading Immuno-Oncology Drug Nivolumab in Lung Cancer Patients Business Wire
Oct-27-16 08:15AM  Clinical Validation Study for RosettaGX Reveal Published in the Journal of Clinical Pathology Business Wire
Oct-24-16 08:30AM  RosettaGX Reveal Analytical Validation Study Featured on the Cover of the October Issue of Cancer Cytopathology Business Wire
Oct-20-16 08:40AM  Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer Business Wire +5.69%
Oct-03-16 08:00AM  Rosetta Genomics Fortifies Intellectual Property Portfolio with Two New Patent Allowances for its Novel microRNA Platform Technology Business Wire
Sep-29-16 10:54AM  Rosetta Genomics Enters Distribution Agreement for RosettaGX Reveal in Israel with Rhenium Business Wire
Sep-27-16 07:42AM  Edited Transcript of ROSG earnings conference call or presentation 26-Sep-16 8:30pm GMT -6.38%
Sep-26-16 04:05PM  Rosetta Genomics Reports 2016 Second Quarter Financial Results Business Wire
07:07AM  Q2 2016 Rosetta Genomics Ltd Earnings Release - After Market Close
Sep-20-16 08:00AM  Rosetta Genomics to Host 2016 Second Quarter Financial Results and Business Update Conference Call on September 26, 2016 Business Wire
Sep-19-16 09:00AM  Rosetta Genomics to Present at Upcoming September Conferences Business Wire
Sep-14-16 09:09AM  Data Validating the Utility of RosettaGX Reveal with Liquid-based Cytology Samples will be Presented at the 86th Annual Meeting of the American Thyroid Association Business Wire
Sep-07-16 08:30AM  RosettaGX Reveal Thyroid miRNA Classifier Now Available to Be Utilized on ThinPrep® Samples Business Wire +9.20%
Aug-24-16 09:00AM  Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for Clinical Study in Prostate Cancer Business Wire
Aug-04-16 08:15AM  Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect from Admera Health Business Wire
Aug-02-16 08:15AM  Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement with Galaxy Health Network for Entire Suite of Diagnostic Tests and Services Business Wire
Jul-11-16 12:05PM  Rosetta Genomics Gets Patent Allowance For microRNA-based Ovarian Cancer Treatment
08:59AM  Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment Business Wire
Jul-06-16 08:00AM  Rosetta Genomics to Present at Cantor Fitzgeralds 2nd Annual Healthcare Conference Business Wire
Jun-23-16 08:00AM  Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of Diagnostic Tests and Services Business Wire
Jun-22-16 01:01PM  Rosetta Genomics Ltd. :ROSG-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 -7.09%
Jun-21-16 11:19AM  Heres Why These Five Stocks Are Gaining Ground on Tuesday at Insider Monkey +11.40%
09:12AM  Rosetta Genomics Receives Approval from New York State for HEME FISH-based Assays Business Wire
May-26-16 07:00AM  Rosetta Genomics Announces Publication of Data Confirming Analytical Validity of its Novel Thyroid Nodule Classification Assay Business Wire +9.73%
May-23-16 08:00AM  Rosetta Genomics Receives Approval from New York State for Four PCR-Based Assays Business Wire
May-19-16 03:41PM  Edited Transcript of ROSG earnings conference call or presentation 19-May-16 2:00pm GMT -13.11%
08:00AM  Rosetta Genomics Reports 2016 First Quarter Financial Results Business Wire
07:07AM  Q1 2016 Rosetta Genomics Ltd Earnings Release - Before Market Open
May-16-16 08:00AM  Rosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on May 19, 2016 Business Wire
Apr-13-16 09:35AM  Rosetta Genomics Ltd. :ROSG-US: Earnings Analysis: Q4, 2015 By the Numbers
09:01AM  Rosetta Genomics Ltd. :ROSG-US: Earnings Analysis: 2015 By the Numbers
Mar-29-16 01:04PM  ROSETTA GENOMICS LTD. Financials -7.50%
Mar-28-16 03:15PM  ROSG: Revenue Growth Accelerated in 4Q15
Mar-23-16 04:26PM  Rosetta Genomics Reports 2015 Full Year Financial Results at noodls
04:05PM  Rosetta Genomics Reports 2015 Full Year Financial Results Business Wire
07:07AM  Full Year 2015 Rosetta Genomics Ltd Earnings Release - Time Not Supplied
Mar-17-16 08:30AM  Rosetta Genomics to Host Business Update and 2015 Year-End Financial Results Conference Call on March 23, 2016 Business Wire
Feb-29-16 09:00AM  Rosetta Genomics Appoints Ana C. Ward as Executive Vice President, Legal and Corporate Development Business Wire
Feb-25-16 09:00AM  Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of Three New Product Offerings Business Wire
Feb-18-16 09:00AM  Rosetta Genomics Receives Approval from New York State for First-of-its-kind Thyroid Cancer Diagnostic Assay Business Wire +19.15%
Feb-08-16 08:00AM  Rosetta Genomics to Present at Source Capital's 2016 Disruptive Growth & Healthcare Conference Business Wire
Feb-01-16 02:22PM  Rosetta Genomics Announces Agreement with Americas Choice Provider Network for Entire Suite of Diagnostic Tests and Services at noodls
08:00AM  Rosetta Genomics Announces Agreement with Americas Choice Provider Network for Entire Suite of Diagnostic Tests and Services Business Wire
Jan-25-16 02:27PM  Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for Classification of Kidney Tumors at noodls +8.43%
08:00AM  Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for Classification of Kidney Tumors Business Wire
Jan-11-16 10:19AM  CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer Business Wire
Jan-06-16 08:00AM  Rosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the Development of Oncology Therapeutics Business Wire -5.04%
Dec-18-15 04:16PM  Rosetta Genomics (ROSG) Stock Closed Up on Cantor Fitzgerald Rating at TheStreet
10:47AM  4 Stocks Under $10 Showing Great Upside Today Accesswire
06:44AM  4 Biotech Stocks Under $10 Poised for Big Breakouts at TheStreet
05:50AM  Coverage initiated on Rosetta Genomics by Cantor Fitzgerald
Dec-14-15 08:00AM  Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA Profiling of Circulating Tumor Cells to Enhance Lung Cancer Diagnosis Business Wire
Dec-02-15 02:00PM  ROSG Reports Record Revenue for Third Quarter 2015 -11.03%
Dec-01-15 08:00AM  Rosetta Genomics Reports Third Quarter 2015 Financial Results Business Wire
Nov-24-15 08:30AM  Rosetta Genomics to Present at the LD Micro Main Event Accesswire -8.98%
Nov-12-15 08:58AM  Rosetta Provides Update on Performance Data and Launch of RosettaGX Reveal (Thyroid microRNA Classifier) Business Wire
Nov-04-15 08:30AM  Rosetta Genomics Appoints Dr. Maria Fe Paz as Interim Chief Medical Officer Business Wire
Oct-27-15 04:15PM  ROSG: Rosetta Reports Strong Revenue Growth for 1H15
Oct-26-15 05:19PM  Rosetta Genomics Reports Financial Results for the First Half of 2015 Business Wire
Oct-21-15 09:20AM  Positive Performance Data from Validation Study of Rosetta Genomics microRNA-based Diagnostic Assay for Thyroid Nodule Classification Presented at the International Thyroid Congress and Annual Meeting of the American Thyroid Association Business Wire
Oct-20-15 08:30AM  Rosetta Genomics to Host Business Update and Six Month Financials Conference Call on October 27, 2015 Business Wire
Oct-14-15 07:00AM  Rosetta Genomics Raises $8,000,000 in Private Placement Business Wire -8.63%
Oct-12-15 08:30AM  Rosetta Genomics Launches BRAF Mutation Assay Business Wire
Oct-01-15 08:30AM  Rosetta Genomics to Present at 2015 Aegis Growth Conference Business Wire
Sep-30-15 09:15AM  Rosetta Genomics to Partner with FNApath to Provide Centralized Laboratory Testing Services for Thyroid Cancer GlobeNewswire
Sep-22-15 08:57AM  Rosetta Genomics Receives U.S. Patent for Treatment of Prostate Cancer Business Wire
Sep-08-15 03:30PM  CORRECTING and REPLACING Rosetta Genomics to Present at the 17th Annual Rodman & Renshaw Global Investment Conference Business Wire
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.